NCT03891953: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.

NCT03891953
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: TNBC patients are only eligible for the expansion phase & must not have received prior anti-PD-1/PD-L1 therapy 
Exclusions: Patients with symptomatic central nervous system (CNS) metastases that require treatment- stable metastases allowed- see trial for details
https://ClinicalTrials.gov/show/NCT03891953

Comments are closed.

Up ↑